ATE421535T1 - Peg-modifiziertes erythropoietin - Google Patents

Peg-modifiziertes erythropoietin

Info

Publication number
ATE421535T1
ATE421535T1 AT01970285T AT01970285T ATE421535T1 AT E421535 T1 ATE421535 T1 AT E421535T1 AT 01970285 T AT01970285 T AT 01970285T AT 01970285 T AT01970285 T AT 01970285T AT E421535 T1 ATE421535 T1 AT E421535T1
Authority
AT
Austria
Prior art keywords
peg
epo
conjugated
native
erythropoietin
Prior art date
Application number
AT01970285T
Other languages
English (en)
Inventor
Teruo Nakamura
Yasuo Sekimori
Minoru Machida
Hiromitsu Kawata
Hajime Miyamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE421535T1 publication Critical patent/ATE421535T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01970285T 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin ATE421535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000315421 2000-10-16

Publications (1)

Publication Number Publication Date
ATE421535T1 true ATE421535T1 (de) 2009-02-15

Family

ID=18794529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01970285T ATE421535T1 (de) 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin

Country Status (8)

Country Link
US (2) US20040082765A1 (de)
EP (1) EP1333036B1 (de)
JP (1) JP5170931B2 (de)
AT (1) ATE421535T1 (de)
AU (1) AU2001290312A1 (de)
DE (1) DE60137525D1 (de)
ES (1) ES2320101T3 (de)
WO (1) WO2002032957A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2509755A1 (en) 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
EP1471153A3 (de) * 2003-03-21 2005-06-15 F. Hoffmann-La Roche Ag Transkriptionsaktivitätsassay
KR20060032140A (ko) * 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
WO2005058366A2 (en) * 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
DK1699915T3 (da) * 2003-12-30 2010-09-13 Augustinus Bader Anvendelse af erythropoietin til levervævsregenerering
EP1848461A2 (de) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Konjugate einer epo-gruppierung und eines polymers
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
WO2007026772A1 (ja) * 2005-08-31 2007-03-08 Kaneka Corporation ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
JP2009532351A (ja) 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
CN101511391B (zh) * 2006-07-25 2013-03-13 利普生技术有限公司 N末端聚唾液酸化
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
JP5723528B2 (ja) * 2006-08-04 2015-05-27 プロロング ファーマシューティカルズ エルエルシー 修飾されたエリスロポエチン
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
EP3175863B1 (de) 2009-05-20 2021-12-01 BioMarin Pharmaceutical Inc. Varianten des natriuretischen peptids typ c
CA2773596C (en) 2009-09-15 2017-11-28 Kaneka Corporation Modified erythropoietin to which water-soluble long-chain molecule is added
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2502646B2 (ja) 1988-01-19 1996-05-29 松下電器産業株式会社 バ―ナ
JPH029900A (ja) * 1988-04-12 1990-01-12 Kirin Amgen Inc 修飾エリスロポエチン
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NO934477L (no) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG hydrazon- og PEG oksim-bindingdannende reagenser og proteinderivater derav
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996028475A1 (fr) * 1995-03-10 1996-09-19 Nakamura, Toshikazu Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
JP4410852B2 (ja) * 1996-08-02 2010-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 単一の共有結合ｎ末端水溶性ポリマーを有するポリペプチド
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
BR9812267B1 (pt) * 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
EP1144613B2 (de) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Verfahren zur herstellung von proteinen mit freien cysteinresten
EA004685B1 (ru) 1999-01-29 2004-06-24 Эмджен Инк. Конъюгаты гксф
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina

Also Published As

Publication number Publication date
US20060276634A1 (en) 2006-12-07
EP1333036A1 (de) 2003-08-06
US20040082765A1 (en) 2004-04-29
US8022191B2 (en) 2011-09-20
AU2001290312A1 (en) 2002-04-29
JPWO2002032957A1 (ja) 2004-02-26
ES2320101T3 (es) 2009-05-19
JP5170931B2 (ja) 2013-03-27
EP1333036B1 (de) 2009-01-21
WO2002032957A1 (fr) 2002-04-25
EP1333036A4 (de) 2004-09-29
DE60137525D1 (de) 2009-03-12

Similar Documents

Publication Publication Date Title
ATE421535T1 (de) Peg-modifiziertes erythropoietin
DE60006100D1 (de) Lang wirkende insulinotrope peptide
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
ATE551362T1 (de) Peptide, die den blutzuckergehalt senken
BR0010757A (pt) Inibidores de peptìdeo de fusão de longa duração de infecção viral
ATE550041T1 (de) Transglutaminase-vermittelte konjugation von peptiden
ATE364654T1 (de) Polyamideketten von genauer länge und deren konjugate mit proteinen
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
AU2001296962A1 (en) Pegylated interleukin-10
ATE89743T1 (de) Conjugate dichter sterne.
EA200400067A1 (ru) Конъюгаты гксф
CO5190661A1 (es) Derivados de la eritropoyetina
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
DK1274728T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
ATE505204T1 (de) Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
DE69432141D1 (de) Taxane mit furyl-oder thienyl substituierten seitenketten
DE60236796D1 (de) Verzweigte polyalkylenglykole
DK0557199T3 (da) Polyethylenglycol-hirudin-konjugater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af tromboser
CA2373252A1 (en) Long lasting anti-angiogenic peptides
TR200200599T2 (tr) İnsan insülini monomerik analogları.
WO2004014951A3 (en) Binding molecules
CY1115962T1 (el) Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
YU29492A (sh) Konjugati proteina sa polietilenom
ITAR930014A1 (it) Snodo rotante per collane e bracciali tubolari

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1333036

Country of ref document: EP